These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

312 related articles for article (PubMed ID: 8865549)

  • 21. Factor VIII assays in haemophilia a patients treated with ReFacto.
    Sukhu K; Harrison P; Keeling D
    Br J Haematol; 2003 Apr; 121(2):379-80. PubMed ID: 12694265
    [No Abstract]   [Full Text] [Related]  

  • 22. CLINICAL PROBLEM-SOLVING. A Bruising Loss.
    Gibson CJ; Berliner N; Miller AL; Loscalzo J
    N Engl J Med; 2016 Jul; 375(1):76-81. PubMed ID: 27406351
    [No Abstract]   [Full Text] [Related]  

  • 23. The Rodin (Research Of Determinants of INhibitor Development among PUPs with haemophilia) study: the clinical conundrum from the perspective of haemophilia treaters.
    Kessler CM; Iorio A
    Haemophilia; 2013 May; 19(3):351-4. PubMed ID: 23577743
    [No Abstract]   [Full Text] [Related]  

  • 24. Acquired circulating anticoagulants in hemophilia A.
    Strauss HS
    N Engl J Med; 1969 Oct; 281(16):866-73. PubMed ID: 5812255
    [No Abstract]   [Full Text] [Related]  

  • 25. [Wilate--the first VWF/FVIII of the second generation--newly introduced in Germany].
    Pharm Unserer Zeit; 2006; 35(1):83. PubMed ID: 16465869
    [No Abstract]   [Full Text] [Related]  

  • 26. Successful endoscopic sphincterotomy for choledocholithiasis in a patient with severe hemophilia A and inhibitors.
    Sugiura R; Kuwatani M; Kawakubo K; Sano I; Kato S; Endo T; Sakamoto N
    Clin J Gastroenterol; 2018 Jun; 11(3):188-192. PubMed ID: 29396835
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Inhibitor challenges in the paediatric setting.
    Sieger L; Aledort L
    Haemophilia; 2006 Jan; 12(1):106-7. PubMed ID: 16409186
    [No Abstract]   [Full Text] [Related]  

  • 28. The optimal treatment for haemophiliacs who have developed factor VIII or -IX antibodies.
    Engelfriet CP; Reesink HW; Mannucci PM; Gringeri A; Ingerslev J; Brettler DB; Mauser-Bunschoten EP; Negrier C; Berntorp E; Smith OP; Shapiro AD
    Vox Sang; 2000; 78(4):256-61. PubMed ID: 10970234
    [No Abstract]   [Full Text] [Related]  

  • 29. Factor VIII inhibitor in a patient with mild hemophilia A.
    Lechner K; Ludwig E; Niessner H; Thaler E
    Haemostasis; 1972-1973; 1(5):261-70. PubMed ID: 4594778
    [No Abstract]   [Full Text] [Related]  

  • 30. Clinicohaematological profile of two cases of inhibitors to factor VIII.
    Shanthala Devi AM; Srikrishna A; Sitalaksmi S; Damodar P
    Indian J Pathol Microbiol; 2001 Jul; 44(3):365-6. PubMed ID: 12024937
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Hemophilia market awaits next-generation therapies.
    Sheridan C
    Nat Biotechnol; 2011 Nov; 29(11):960. PubMed ID: 22068523
    [No Abstract]   [Full Text] [Related]  

  • 32. [Side-effects of factor VIII substitution in patients with hemophilia A (author's transl)].
    Tilsner V; Reuter H
    MMW Munch Med Wochenschr; 1982 Jun; 124(22):553-7. PubMed ID: 6808385
    [No Abstract]   [Full Text] [Related]  

  • 33. Summary of clinical experience with recombinant factor VIII products--Recombinate.
    White GC
    Ann Hematol; 1994; 68 Suppl 3():S7-8. PubMed ID: 8180260
    [No Abstract]   [Full Text] [Related]  

  • 34. [Percutaneous nephrolithotripsy supported by recombinant factor VIII in a patient with hemophilia A, a Jehovah's Witness].
    Azuno Y; Kaku K
    Rinsho Ketsueki; 1995 Dec; 36(12):1337-41. PubMed ID: 8587168
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Inhibitors in mild/moderate haemophilia A: an update.
    Franchini M; Salvagno GL; Lippi G
    Thromb Haemost; 2006 Aug; 96(2):113-8. PubMed ID: 16894451
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Recombinant factor VIII: an introduction.
    Büchel KH
    Semin Hematol; 1991 Apr; 28(2 Suppl 1):1-4. PubMed ID: 1908119
    [No Abstract]   [Full Text] [Related]  

  • 37. Immune reconstitution inflammatory syndrome (IRIS) as a cause for inhibitor development in hemophilia.
    Werwitzke S; Tiede A; Stoll M; von Depka M
    J Thromb Haemost; 2004 Jan; 2(1):193-4. PubMed ID: 14717985
    [No Abstract]   [Full Text] [Related]  

  • 38. Incidence of inhibitors in patients with severe and moderate hemophilia A treated with factor VIII concentrates.
    Schwarzinger I; Pabinger I; Korninger C; Haschke F; Kundi M; Niessner H; Lechner K
    Am J Hematol; 1987 Mar; 24(3):241-5. PubMed ID: 3103425
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Porcine factor VIII therapy in patients with congenital hemophilia and inhibitors: efficacy, patient selection, and side effects.
    Hay CR; Lozier JN; Lee CA; Lafan M; Tradati H; Santagostino E; Ciavarella N; Schiavoni M; Fukui H; Yoshioka A
    Semin Hematol; 1994 Apr; 31(2 Suppl 4):20-5. PubMed ID: 7939768
    [No Abstract]   [Full Text] [Related]  

  • 40. [Production of factor VIII preparations and their use in the substitution therapy of hemophilia A].
    Gaerisch F; Stein P
    Z Gesamte Inn Med; 1982 Oct; 37(19):641-4. PubMed ID: 6817530
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.